Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SKYE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Delisting (new) — Company received formal Nasdaq notice for failing minimum stockholders' equity requirement, creating delisting risk.
Skye Bioscience receives Nasdaq delisting warning over equity shortfall
Filed May 15, 2026 · Period ending May 13, 2026 · ~1 min read
Key Changes
-
high
Nasdaq notified Skye on May 13 that its stockholders' equity of $9.0M falls below the required $10M minimum for continued listing on the Global Market. Stock continues trading under SKYE during the compliance period.
Item 3.01 verify on EDGAR → -
high
Company has until June 29 to submit a compliance plan to Nasdaq. If accepted, Skye could receive up to 180 days (until November 9) to demonstrate it meets the equity requirement.
Item 3.01 verify on EDGAR → -
high
Management is evaluating options to regain compliance but explicitly states there is no assurance the company will successfully meet listing requirements or avoid delisting.
Item 3.01 verify on EDGAR →
Summary
Skye Bioscience disclosed it received a deficiency notice from Nasdaq after its March 2026 quarterly report showed stockholders' equity of $9.0 million, falling $1 million short of the exchange's $10 million minimum requirement for Global Market listing. The notice does not immediately halt trading, but it starts a compliance clock that could ultimately lead to delisting if the company cannot remedy the shortfall.
For retail investors, this is a material warning sign about the company's financial health and market access. Delisting from a major exchange typically reduces liquidity, increases trading costs, and can trigger institutional selling due to investment mandates. The company has acknowledged it's exploring options but provided no assurance it can fix the problem. Watch for Skye's compliance plan submission by June 29.
If Nasdaq rejects the plan or the company fails to restore equity levels by November, delisting becomes increasingly likely. Investors should also monitor whether management pursues dilutive financing, asset sales, or other capital-raising measures that could impact share value.
Section-by-Section Diff
Event · Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
The Company is currently evaluating various alternative courses of action to regain compliance. There can be no assurance that the Company will be able to regain compliance with the minimum stockholders’ equity requirement or maintain compliance with the other listing requirements.
Management is exploring options to address the deficiency but explicitly states there is no guarantee the company will successfully regain or maintain compliance with Nasdaq listing standards. This disclosure highlights material uncertainty about the company's ability to remain listed on the Nasdaq Global Market.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify